Group 1 - The stock price of Haixiang Pharmaceutical (002099) closed at 6.27 yuan on August 5, 2025, with a slight increase of 0.16% and a turnover rate of 0.96% [1] - On August 5, the net outflow of main funds was 877.82 million yuan, while retail investors saw a net inflow of 683.46 million yuan [2][4] - The company announced a share repurchase plan on April 9, 2025, with a total repurchase amount set between 150 million yuan and 300 million yuan, and a maximum repurchase price of 7.46 yuan per share [2] Group 2 - On August 5, 2025, Haixiang Pharmaceutical repurchased 850,000 shares through centralized bidding, accounting for 0.05% of the total share capital, with a total transaction amount of 5,326,664 yuan [2][4] - The company plans to continue the repurchase based on market conditions and will fulfill its information disclosure obligations [2]

Group 1 - The company Zhejiang Haixiang Pharmaceutical Co., Ltd. has approved a share repurchase plan using its own funds, with a total repurchase amount between RMB 150 million and RMB 300 million, and a maximum repurchase price of RMB 7.46 per share [1][2] - The first share repurchase involved buying back 850,000 shares, which represents 0.05% of the company's total share capital, with a total transaction amount of RMB 5,326,664, at prices ranging from RMB 6.24 to RMB 6.29 per share [1][2] - The repurchase plan is in compliance with relevant laws and regulations, and the company will continue to implement the plan based on market conditions within the specified timeframe [2]

证券日报网讯8月5日晚间，海翔药业（002099）发布公告称，2025年8月5日，公司首次通过股票回购专 用证券账户以集中竞价交易方式回购公司股份850，000股，占公司总股本的0.05%。 ...

Group 1 - Company HaiXiang Pharmaceutical announced a stock buyback of 850,000 shares, representing 0.05% of its total share capital, with a total transaction amount of approximately 5.33 million RMB [2] - The buyback occurred on August 5, 2025, with a maximum transaction price of 6.29 RMB per share and a minimum price of 6.24 RMB per share [2] Group 2 - For the year 2024, the revenue composition of HaiXiang Pharmaceutical is as follows: 70.59% from the pharmaceutical manufacturing sector, 28.47% from the dye industry, and 0.94% from other sources [2]

Core Viewpoint - Haishang Pharmaceutical (002099.SZ) announced a share buyback of 850,000 shares, representing 0.05% of the total share capital, at a total cost of approximately 5.33 million RMB [1] Group 1 - The company conducted the buyback through a dedicated securities account via centralized bidding [1] - The highest transaction price was 6.29 RMB per share, while the lowest was 6.24 RMB per share [1] - The total amount spent on the buyback was 5.326664 million RMB, excluding transaction fees [1]

Core Viewpoint - The company has initiated a share buyback program, demonstrating confidence in its stock value and commitment to returning capital to shareholders [1] Summary by Categories Share Buyback Details - The company repurchased 850,000 shares, representing 0.05% of its total share capital [1] - The highest transaction price was 6.29 CNY per share, while the lowest was 6.24 CNY per share [1] - The total amount spent on the buyback was 5.3267 million CNY, excluding transaction fees [1] Compliance and Strategy - The buyback is in accordance with relevant laws and regulations [1] - The action aligns with the company's established buyback plan [1]

证券代码：002099 证券简称：海翔药业 公告编号：2025-035 浙江海翔药业股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 一、首次回购公司股份的具体情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— ...

Company Overview - Haisheng Pharmaceutical's latest stock price is 6.26 yuan, an increase of 0.04 yuan from the previous trading day [1] - The stock reached a high of 6.27 yuan and a low of 6.06 yuan during the trading session, with a trading volume of 188,012 hands and a transaction amount of 116 million yuan [1] Industry Information - The company operates in the chemical pharmaceutical industry, focusing on the research, development, production, and sales of pharmaceutical raw materials and intermediates [1] - Its product range includes treatments for various fields such as anti-infection, cardiovascular, and mental health [1] Shareholder and Market Data - As of July 31, 2025, the number of shareholders for Haisheng Pharmaceutical is 30,100, a decrease of 1,001 from the previous period [1] - The average number of circulating shares held per shareholder increased from 52,000 to 53,700 shares, with an average circulating market value of 335,100 yuan [1] - The number of shares held through the Shenzhen Stock Connect is 12.69 million, accounting for 0.78% of the circulating share capital [1] Capital Flow - On August 4, the net outflow of main funds was 13.89 million yuan, representing 0.14% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 354,700 yuan [1]

证券代码：002099 证券简称：海翔药业 公告编号：2025-034 浙江海翔药业股份有限公司 关于为合并报表范围内子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，公司与招商银行股份有限公司台州分行重新签署《最高额不可撤销担 保书》，同意公司继续为金沣医药申请商业汇票、信用证、保函等各类融资提供 5,000 万元人民币连带保证责任。本次对外担保系原担保展期，未新增额度。 三、担保书的主要内容 1、担保金额：5,000 万元人民币。 2、担保方式：连带保证责任。 一、担保情况概述 浙江海翔药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 28 日 召开了第七届董事会第十四次会议,2025 年 5 月 21 日召开了 2024 年年度股东大 会，审议通过了《关于为合并报表范围内子公司提供担保额度的议案》，同意为 合并报表范围内子公司台州金沣医药化工有限公司（以下简称"金沣医药"）提 供不超过人民币 10,000 万元（或等值外币）担保额度。具体详见公司于 2025 年 4 月 29 日在《证券时报》《证券日报》和巨 ...

Group 1 - The core point of the article is that Haixiang Pharmaceutical announced on the evening of August 1 that as of July 31, 2025, the company has not yet started the implementation of the current share repurchase plan [2]